Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) EPS (Basic) (2019 - 2025)

Legend Biotech filings provide 7 years of EPS (Basic) readings, the most recent being $0.0 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 100.0% to $0.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.12, a 100.0% increase, with the full-year FY2025 number at $0.0, up 100.07% from a year prior.
  • EPS (Basic) hit $0.0 in Q4 2025 for Legend Biotech, up from -$1.04 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $122916.7 in Q4 2024 to a low of -$948228.6 in Q2 2024.
  • Median EPS (Basic) over the past 5 years was -$2.23 (2023), compared with a mean of -$45852.5.
  • The widest YoY moves for EPS (Basic): up 3055659.39% in 2024, down 17142757.14% in 2024.
  • Legend Biotech's EPS (Basic) stood at -$0.31 in 2021, then crashed by 36.23% to -$0.43 in 2022, then tumbled by 841.71% to -$4.02 in 2023, then surged by 3055659.39% to $122916.7 in 2024, then plummeted by 100.0% to $0.0 in 2025.
  • The last three reported values for EPS (Basic) were $0.0 (Q4 2025), -$1.04 (Q3 2025), and -$3.36 (Q2 2025) per Business Quant data.